By The ASCO Post StaffDecember 10, 2019 In a new effort to improve early breast cancer detection and reduce false-positive exams in women with dense breasts, the American College of Radiology (ACR), the Breast Cancer Research Foundation (BCRF), and GE Healthcare are partnering to support the…
Early-stage research demonstrated the synergistic effects of a novel nanoparticle drug–delivery system to activate an immune pathway in combination with tumor-targeting agents for pancreatic ductal…
The rate of human papillomavirus (HPV) vaccination may be lower among female individuals with mental health issues or neurodevelopmental conditions compared with their peers, according…
Researchers explored whether measuring proinflammatory cytokine levels could effectively identify patients with type 2 diabetes who may be at a higher risk of developing certain…
For relapsed or refractory multiple myeloma, there are three available bispecific antibodies—two that target B-cell maturation antigen (BCMA) and one that targets G protein–coupled receptor…
Annual mammographic screening appeared to be associated with a reduced risk of late-stage breast cancer and an overall survival benefit across clinical and demographic subgroups…
Among children with ALL, half of relapses arise in patients initially classified as having standard-risk disease. In a recent report, researchers aimed to identify potential…
“The use of ruxolitinib was associated with relatively high rates of skin/joint responses and overall chronic graft-vs-host disease (GVHD) responses, improvement in patient-reported outcomes, low…
Meta-analyses of trials of immune checkpoint inhibitors (ICIs) in patients with advanced EGFR-mutated NSCLC progressing on EGFR tyrosine kinase inhibitor treatment indicate that the optimal…
A Chinese single-center trial found that site-specific therapy guided by a 90-gene expression assay improved progression-free survival vs empirical chemotherapy in previously untreated patients with…
On March 19, 2024, ponatinib (Iclusig) was granted accelerated approval for use with chemotherapy in adults with newly diagnosed Philadelphia chromosome–positive acute lymphoblastic leukemia (ALL). Po…
